This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
marijuana: Archive
5 Sector ETFs That Beat the Market in Q3
by Sweta Killa
After a solid start to the third quarter, Wall Street lost momentum on fears of higher rates for a longer-than-expected period and a slowing Chinese economy.
XESNegative Net Change MLPONegative Net Change MSOSNegative Net Change URNJNegative Net Change
electric-vehicles energy etfs marijuana
Behind the Recent Surge in Marijuana ETFs
by Sanghamitra Saha
In a significant development, the Department of Health and Human Services (HHS) has recently initiated a review of marijuana's classification under the Controlled Substances Act.
YOLOPositive Net Change CNBSNegative Net Change MSOSNegative Net Change WEEDNegative Net Change MSOXNegative Net Change
etfs marijuana
Cannabis ETFs Soar on Hopes of Federal Legalization
by Sweta Killa
Marijuana stocks have been surging following a proposal by the Drug Enforcement Agency (???DEA???) to reclassify cannabis as a substance with reduced risk, fueling anticipation of federal legalization.
YOLOPositive Net Change CNBSNegative Net Change MSOSNegative Net Change WEEDNegative Net Change
etfs marijuana
Cannabis ETFs Surge on Legalization Hopes: More Run Ahead?
by Sanghamitra Saha
The prospect of marijuana reclassification has injected newfound optimism into the cannabis investment landscape.
MJNegative Net Change YOLOPositive Net Change MSOSNegative Net Change
etfs marijuana
SAFE Banking Act Resurgence Boosts Pot ETFs: A New Era Ahead?
by Sanghamitra Saha
A fresh wave of investment opportunities emerges as the SAFE Banking Act is reintroduced to Congress, promising brighter prospects for marijuana stocks and ETFs.
MJNegative Net Change YOLOPositive Net Change CNBSNegative Net Change MSOSNegative Net Change
etfs marijuana
Is Tilray Brands (TLRY) A Buy Ahead of Fiscal Q3 Earnings Announcement?
by Bryan Hayes
Industry headwinds still present a major challenge.
TLRYPositive Net Change
cannabis earnings investing marijuana meme-stocks pot-stocks
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.
JAZZPositive Net Change AMRNPositive Net Change AXSMPositive Net Change ALLONo Net Change
cannabis earnings marijuana medical
ETF Laggards of 2022 That Are Leading This Year
by Sweta Killa
While the rally has been broad based, the laggards of last year, like technology and communication services sectors as well as growth and small-cap stocks, have been outperforming this year.
ARKKNegative Net Change JSMLNo Net Change XLCPositive Net Change MEMENegative Net Change WGMINegative Net Change
bitcoin communications etfs marijuana tech-stocks
Top and Flop ETFs of 2022
by Sweta Killa
We have highlighted three ETFs, each from the best and worst-performing zones of 2022.
OIHNegative Net Change TURNegative Net Change BDRYPositive Net Change PFIXNegative Net Change
energy etfs marijuana tech-stocks
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
GILDNegative Net Change VRTXNegative Net Change JAZZPositive Net Change
marijuana